Citation Impact
Citing Papers
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
2007
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Thyroid cancer
2016 Standout
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
2007
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
2009
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Nasopharyngeal carcinoma
2019 Standout
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Antibody therapy of cancer
2012 Standout
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
2010
Validation of novel imaging methodologies for use as cancer clinical trial end-points
2008
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community
2013
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
2016 Standout
Promise and pitfalls of quantitative imaging in oncology clinical trials
2012
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
2010 Standout
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations
2008
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
2008
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
2008
Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations
2008
Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives
2008
18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
2011
Inflammation in Atherosclerosis
2009 Standout
Standards for PET Image Acquisition and Quantitative Data Analysis
2009
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Hepatocellular carcinoma
2022 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
2006
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Diabetes and Cancer
2010 Standout
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
2007
Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
2010
Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin
2007
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
2007
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
2010
Monitoring cancer treatment with PET/CT: does it make a difference?
2007
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
2009
Works of S.L. Bacharach being referenced
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
2006